Ascendis Pharma Investigational Site
Wilrijk 2610
0 studies enrolling now · 1 studies all time
What they study most
2L+ Cervical Cancer, Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Platinum-resistant Ovarian Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Post Anti-PD-1 Melanoma, Second or Third Line (2L/3L) Cervical Cancer, Third Line or Later (3L+) HER2+ Breast Cancer